Halofenate
Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo[1].
Product Specifications
CAS Number
[26718-25-2]
Product Name Alternative
MK 185
UNSPSC
12352005
Target
PPAR; Wnt; β-catenin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Assay Protocol
https://www.medchemexpress.com/halofenate.html
Smiles
CC(NCCOC(C(C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2)=O)=O
Molecular Formula
C19H17ClF3NO4
Molecular Weight
415.79
References & Citations
[1]Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate)
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human OLFML1 shRNA (UAS) - Lentiviral human OLFML1 shRNA (UAS, GFP) (100)
